AU2018250398B2 - Promoting hair growth and treatment of hair loss or excessive hair shedding - Google Patents

Promoting hair growth and treatment of hair loss or excessive hair shedding Download PDF

Info

Publication number
AU2018250398B2
AU2018250398B2 AU2018250398A AU2018250398A AU2018250398B2 AU 2018250398 B2 AU2018250398 B2 AU 2018250398B2 AU 2018250398 A AU2018250398 A AU 2018250398A AU 2018250398 A AU2018250398 A AU 2018250398A AU 2018250398 B2 AU2018250398 B2 AU 2018250398B2
Authority
AU
Australia
Prior art keywords
minoxidil
hair
range
composition
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018250398A
Other languages
English (en)
Other versions
AU2018250398A1 (en
Inventor
Rodney Sinclair
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Samson Clinical Pty Ltd
Original Assignee
Samson Clinical Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017902722A external-priority patent/AU2017902722A0/en
Application filed by Samson Clinical Pty Ltd filed Critical Samson Clinical Pty Ltd
Publication of AU2018250398A1 publication Critical patent/AU2018250398A1/en
Application granted granted Critical
Publication of AU2018250398B2 publication Critical patent/AU2018250398B2/en
Priority to AU2019203438A priority Critical patent/AU2019203438A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
AU2018250398A 2017-07-12 2018-07-12 Promoting hair growth and treatment of hair loss or excessive hair shedding Active AU2018250398B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2019203438A AU2019203438A1 (en) 2017-07-12 2019-05-16 Promoting hair growth and treatment of hair loss or excessive hair shedding

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2017902722 2017-07-12
AU2017902722A AU2017902722A0 (en) 2017-07-12 Promoting hair growth and treatment of hair loss or excessive hair shedding
PCT/AU2018/050719 WO2019010535A1 (en) 2017-07-12 2018-07-12 STIMULATION OF HAIR GROWTH AND TREATMENT OF HAIR FALL OR EXCESSIVE ALOPECIA

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2019203438A Division AU2019203438A1 (en) 2017-07-12 2019-05-16 Promoting hair growth and treatment of hair loss or excessive hair shedding

Publications (2)

Publication Number Publication Date
AU2018250398A1 AU2018250398A1 (en) 2019-01-31
AU2018250398B2 true AU2018250398B2 (en) 2019-02-28

Family

ID=65001077

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018250398A Active AU2018250398B2 (en) 2017-07-12 2018-07-12 Promoting hair growth and treatment of hair loss or excessive hair shedding
AU2019203438A Abandoned AU2019203438A1 (en) 2017-07-12 2019-05-16 Promoting hair growth and treatment of hair loss or excessive hair shedding

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2019203438A Abandoned AU2019203438A1 (en) 2017-07-12 2019-05-16 Promoting hair growth and treatment of hair loss or excessive hair shedding

Country Status (10)

Country Link
US (2) US20190269684A1 (enExample)
EP (1) EP3651769B1 (enExample)
JP (2) JP7191927B2 (enExample)
KR (2) KR20240064747A (enExample)
CN (1) CN111065396A (enExample)
AU (2) AU2018250398B2 (enExample)
CA (1) CA3069336A1 (enExample)
ES (1) ES2909395T3 (enExample)
SG (1) SG11202000124PA (enExample)
WO (1) WO2019010535A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3626244B1 (en) 2014-10-29 2023-06-07 Samson Clinical Pty Ltd. Oral minoxidil for the treatment of alopecia areata
US12364696B2 (en) 2019-02-27 2025-07-22 Jak Slave Pty Ltd Treatment of autoimmune disease
EP4114362A4 (en) * 2020-03-05 2024-03-20 University of Miami NANODRUG FORMULATIONS OF CANNABIDIOL AND THEIR METHODS OF USE
CN112691187B (zh) * 2020-12-30 2021-12-21 深圳新发源植物科技发展有限公司 一种用于防止额前脱发的缓释膜及其制备方法
CN113248501B (zh) * 2021-06-17 2021-10-08 南京韦尔优众医药有限公司 Cly系列化合物及其制备方法和制备药物的用途
JP2025536556A (ja) * 2022-10-25 2025-11-07 ヴェラダーミクス インコーポレイテッド 放出調節ミノキシジル用組成物および使用方法
KR20250034269A (ko) * 2023-09-01 2025-03-11 폴리 인터내셔널 탈모증 치료를 위한 경구 미녹시딜에 대한 경구 보충제용 조성물 및 방법
WO2025051237A1 (zh) * 2023-09-08 2025-03-13 苏州开拓药业股份有限公司 含雄激素受体抑制剂/拮抗剂的药物组合物及方法和用途
GB2638418A (en) * 2024-02-21 2025-08-27 Novumgen Ltd An orodispersible tablet of spironolactone and its process of preparation

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4997643A (en) * 1989-07-12 1991-03-05 Union Carbide Chemicals And Plastics Company Inc. Polymeric salt delivery systems
WO1999040898A2 (en) * 1998-02-12 1999-08-19 Centrapharm Inc. Sublingual drug formulations having combined rapid onset of action and long lasting therapeutic effect
WO2007023396A2 (en) * 2005-05-09 2007-03-01 Foamix Ltd. Vasoactive kit and composition and uses thereof
US20070166362A1 (en) * 2004-10-07 2007-07-19 Shuji Sakuma Transdermal and transmucosal preparations
WO2010036947A2 (en) * 2008-09-27 2010-04-01 Jina Pharmaceuticals, Inc. Lipid based pharmaceutical preparations for oral and topical application; their compositions, methods, and uses thereof
WO2012140252A1 (en) * 2011-04-15 2012-10-18 Bionanoplus, S.L. Nanoparticles comprising esters of poly (methyl vinyl ether-co-maleic anhydride) and uses thereof
AU2011100917B4 (en) * 2011-07-26 2013-05-02 Sinclair, Rodney Daniel Professor Treatment of male and female androgenetic alopecia with oral minoxidil either alone or in combination with antiandrogens
WO2013181487A2 (en) * 2012-05-31 2013-12-05 Stiefel Laboratories, Inc. Method of treating
WO2016065426A1 (en) * 2014-10-29 2016-05-06 Samson Clinical Pty Ltd Detection and treatment of excessive hair shedding

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2314019B (en) * 1996-06-10 2000-03-15 Bio Scient Ltd The use of L-Lysine in the treatment of hair loss
JP2009091325A (ja) 2007-10-11 2009-04-30 Rohto Pharmaceut Co Ltd 育毛剤
US9561224B1 (en) * 2015-05-27 2017-02-07 Moshe Rogosnitzky Methods and compositions for treating androgenetic alopecia

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4997643A (en) * 1989-07-12 1991-03-05 Union Carbide Chemicals And Plastics Company Inc. Polymeric salt delivery systems
WO1999040898A2 (en) * 1998-02-12 1999-08-19 Centrapharm Inc. Sublingual drug formulations having combined rapid onset of action and long lasting therapeutic effect
US20070166362A1 (en) * 2004-10-07 2007-07-19 Shuji Sakuma Transdermal and transmucosal preparations
WO2007023396A2 (en) * 2005-05-09 2007-03-01 Foamix Ltd. Vasoactive kit and composition and uses thereof
WO2010036947A2 (en) * 2008-09-27 2010-04-01 Jina Pharmaceuticals, Inc. Lipid based pharmaceutical preparations for oral and topical application; their compositions, methods, and uses thereof
WO2012140252A1 (en) * 2011-04-15 2012-10-18 Bionanoplus, S.L. Nanoparticles comprising esters of poly (methyl vinyl ether-co-maleic anhydride) and uses thereof
AU2011100917B4 (en) * 2011-07-26 2013-05-02 Sinclair, Rodney Daniel Professor Treatment of male and female androgenetic alopecia with oral minoxidil either alone or in combination with antiandrogens
WO2013181487A2 (en) * 2012-05-31 2013-12-05 Stiefel Laboratories, Inc. Method of treating
WO2016065426A1 (en) * 2014-10-29 2016-05-06 Samson Clinical Pty Ltd Detection and treatment of excessive hair shedding

Also Published As

Publication number Publication date
KR20200028403A (ko) 2020-03-16
AU2019203438A1 (en) 2019-06-06
KR102663164B1 (ko) 2024-05-07
KR20240064747A (ko) 2024-05-13
NZ760579A (en) 2024-09-27
JP2020527146A (ja) 2020-09-03
CA3069336A1 (en) 2019-01-17
US20250064807A1 (en) 2025-02-27
EP3651769A4 (en) 2021-04-21
ES2909395T3 (es) 2022-05-06
EP3651769B1 (en) 2022-01-05
SG11202000124PA (en) 2020-02-27
US20190269684A1 (en) 2019-09-05
AU2018250398A1 (en) 2019-01-31
BR112020000508A2 (pt) 2020-07-14
JP2023016964A (ja) 2023-02-02
EP3651769A1 (en) 2020-05-20
CN111065396A (zh) 2020-04-24
JP7191927B2 (ja) 2022-12-19
WO2019010535A1 (en) 2019-01-17

Similar Documents

Publication Publication Date Title
US20250064807A1 (en) Promoting Hair Growth and Treatment of Hair Loss or Excessive Hair Shedding
US6458384B2 (en) Pharmaceutical with predetermined activity profile
AU2017203009B2 (en) Diethylstilbestrol dosage form and use for the treatment of prostate or breast cancer
US20080038355A1 (en) Bioadhesive dosage form of steroids
EP3313408B1 (en) Drospirenone-based contraceptive for a female patient affected with excess weight
US20250381192A1 (en) Treatment of Autoimmune Disease
KR102158948B1 (ko) 약물 전달 시스템
JP2003520239A (ja) ホルモン置換療法用のドロスピレノン
JP2005506987A (ja) 感覚的に許容される口内崩壊性組成物
US20170014340A1 (en) Orally Disintegrating Tablet of Nabilone Comprising Mannitol-Based Granules
AU2022200479A1 (en) Treatment of autoimmune disease
Kulkarni et al. A systematic review on oral drug delivery as a fast dissolving film to improve therapeutic effectiveness
US20250017932A1 (en) Methods of Administering Elagolix
HK40018518B (en) Promoting hair growth and treatment of hair loss or excessive hair shedding
HK40018518A (en) Promoting hair growth and treatment of hair loss or excessive hair shedding
BR112020000508B1 (pt) Composição orodispersível e uso de uma composição orodispersível
BR122025006573A2 (pt) Composição dispersível
EP3108889A1 (en) Drospirenone-based contraceptive for a female patient affected with excess weight
ES2725009T3 (es) Comprimidos con un alto contenido de principios activos útiles para el tratamiento de la pérdida de cabello o la estimulación de su crecimiento
OA18512A (en) Drospirenone-based contraceptive for a female patient affected with excess weight.

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)